Franz Gerner

CTO at Excision BioTherapeutics

Dr. Gerner has more than 25 years of experience in process and analytical development, as well as manufacturing across several therapeutic gene therapy areas.

Prior to joining Excision, Dr. Gerner served as VP, Technical Operations at Sio Gene Therapies, formerly Axovant Gene Therapies, a gene therapy company where he was responsible for development, manufacturing, analytical and supply chain activities for early and late-stage programs based on AAV delivery. As Sr. Director of Technical Innovation and New Technologies at Regenxbio he established strategies for new approaches to increase the yield and improve the purity of AAV vectors. He originally joined Regenxbio at an early stage as Sr. Director of Process Development, being responsible for process/analytical development activities and manufacturing campaigns, and subsequently focusing on building in house process development capacities which led to significant improvements of the manufacturing process for multiple AAV serotypes.


  • CTO

    Current role

View in org chart